SETDB1-TTD-IN-1
Based on 6 publication(s) in Google Scholar
SETDB1-TTD-IN-1 is a SETDB1 methyltransferase activator and SETDB1-TTD competitive inhibitor (Kd of 88 nM), and selectivity for SETDB1-TTD over other tudor and bromodomain proteins. SETDB1-TTD-IN-1 stimulates methyltransferase activity via increased catalytic activity, promotes Akt1 Lys64 methylation, Akt1 Thr308 phosphorylation and activation. SETDB1-TTD-IN-1 prevents SETDB1-TTD-histone H3 peptide association, induces global gene expression changes, exhibits cellular target engagement, and acts as a tool compound for SETDB1-TTD function exploration. SETDB1-TTD-IN-1 can be used for the research of breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 2755823-12-0
- Formule: C28H31N5O2
- Masse moléculaire:469.58
-
Stockage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) SETDB1-TTD-IN-1
MoreVoir tous les produits spécifiques à Isoform Histone Methyltransferase
More
Activité biologique
|
SETDB1/KMT2G |
Akt1 |
SETDB1-TTD-IN-1 (R,R)-59) binds to the purified SETDB1 triple tudor domain with an IC50 of 1.7 μM in a competition TR-FRET assay[1].
SETDB1-TTD-IN-1 binds directly to the purified SETDB1 triple tudor domain with a Kd of 4.8 μM in an SPR assay[1].
SETDB1-TTD-IN-1 (0-100 μM; 60 min) increases full-length SETDB1-mediated methylation of the Akt1-K64 peptide in vitro with an EC50 of 19 μM, enhancing catalytic efficiency by increasing k_cat without altering SAM binding affinity[1].
SETDB1-TTD-IN-1 (2-40 μM; 1-24 h) promotes dose-dependent and time-dependent Akt1 trimethylation and T308 phosphorylation in HA-tagged Akt1-transfected HEK293T cells[1].
SETDB1-TTD-IN-1 (2-40 μM) promotes Akt1 trimethylation and T308 phosphorylation in HA-tagged Akt1-stably expressing DLD1 colorectal adenocarcinoma cells[1].
SETDB1-TTD-IN-1 (2.5-5 μM; 72 h) promotes proliferation of MDA-MB-231 breast cancer cells at concentrations of 2.5 μM and 5 μM after 72 hours of treatment[1].
SETDB1-TTD-IN-1 potently binds purified SETDB1-TTD with a Kd of 0.088 μM as measured by ITC assay[2].
SETDB1-TTD-IN-1 binds purified SETDB1-TTD with a Kd of 0.106 μM as measured by SPR[2].
SETDB1-TTD-IN-1 (100 μM) is highly selective for SETDB1-TTD, showing minimal to no activity against 14 other tudor domains, weak activity against 53BP1-TTD and JMJD2A-TTD, and no or very weak activity against 32 BRD proteins[2].
SETDB1-TTD-IN-1 completely blocks the binding of modified histone H3 peptides (H3K9me/K14ac, H3K9me2/K14ac, H3K9me3/K14ac) to purified SETDB1-TTD after 20 minutes of pretreatment[2].
SETDB1-TTD-IN-1 (0.01-100 μM) potently inhibits the interaction of purified SETDB1-TTD with biotinylated H3K9me2/K14ac (IC50 = 0.93 μM) and H3K9me3/K14ac (IC50 = 0.75 μM) peptides in an HTRF assay[2].
SETDB1-TTD-IN-1 (2.5-40 μM; 6 h) dose-dependently stabilizes SETDB1-TTD protein in SETDB1-TTD-transfected HEK293T cells at concentrations ≥5 μM after 6 hours of treatment[2].
SETDB1-TTD-IN-1 (6 μM; 18 h) increases the mobility of EGFP-tagged wild-type SETDB1-TTD in HEK293T cells after 18 hours of treatment, as shown by a significantly reduced FRAP normalized half-life recovery time[2].
SETDB1-TTD-IN-1 (10 μM; 24 h) significantly alters the expression of 72 genes, including 49 uniquely regulated genes, in THP-1 human acute monocytic leukemia cells after 24 hours of treatment[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T cells (transiently expressing HA-tagged Akt1)
-
Concentration:2 μM, 5 μM, 10 μM, 20 μM, 40 μM
-
Incubation Time:1 h; 2 h; 4 h; 24 h
-
Result:Triggered a dose-dependent and time-dependent increase in Akt1 trimethylation and T308 phosphorylation.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:2.5-5 μM
-
Incubation Time:72 h
-
Result:Stimulated cell proliferation at 2.5 μM and 5 μM; this effect was not observed at doses greater than 5 μM.
Chemical Information
-
CAS No. 2755823-12-0
-
Appearance Solid
-
Masse moléculaire 469.58
-
Formule C28H31N5O2
-
Color White to off-white
-
SMILES
CN1C[C@@H](C2=CC=C(OCC3=CC=CC=C3)C=C2)C[C@@H](NC4=NC5=C(C(N4CC=C)=O)NC=C5)C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
SETDB1 enhances starvation-induced lipophagy by inhibiting m6A-mediated mRNA decay via DDX5 methylation. [Abstract]2026 May 17:1-23. PMID: 42087801 -
Cell Death Dis
SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target. [Abstract]2025 Oct 24;16(1):754. PMID: 41136387 -
BMC Biol
SETDB1 targeting SESN2 regulates mitochondrial damage and oxidative stress in renal ischemia-reperfusion injury. [Abstract]2024 Oct 23;22(1):246. PMID: 39443993 -
J Inflamm Res
Mechanisms of Acetate in Alleviating SETDB1-Linked Neuroinflammation and Cognitive Impairment in a Mouse Model of OSA. [Abstract]2025 May 7:18:5931-5950. PMID: 40357375 -
Mol Cell Endocrinol
Estrogen increases Setdb1 cytoplasmic localization to stabilize Serpinh1 and improve protein homeostasis in osteoblasts. [Abstract]2025 Aug 1:605:112568. PMID: 40324678 -
Exp Hematol
CBX7 inhibitors affect H3K9 methyltransferase-regulated gene repression in leukemic cells. [Abstract]2025 Feb:142:104691. PMID: 39613290
Solvant et solubilité
DMSO : 125 mg/mL (266.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.98 mg/mL (4.22 mM); Clear solution
This protocol yields a clear solution of ≥ 1.98 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Uguen M, et al. SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells. ACS Chem Biol. 2023 Aug 18;18(8):1846-1853. [Content Brief]
[2]. Guo Y, et al. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain. Angew Chem Int Ed Engl. 2021;60(16):8760-8765. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1296 mL | 10.6478 mL | 21.2956 mL | 53.2391 mL |
| 5 mM | 0.4259 mL | 2.1296 mL | 4.2591 mL | 10.6478 mL | |
| 10 mM | 0.2130 mL | 1.0648 mL | 2.1296 mL | 5.3239 mL | |
| 15 mM | 0.1420 mL | 0.7099 mL | 1.4197 mL | 3.5493 mL | |
| 20 mM | 0.1065 mL | 0.5324 mL | 1.0648 mL | 2.6620 mL | |
| 25 mM | 0.0852 mL | 0.4259 mL | 0.8518 mL | 2.1296 mL | |
| 30 mM | 0.0710 mL | 0.3549 mL | 0.7099 mL | 1.7746 mL | |
| 40 mM | 0.0532 mL | 0.2662 mL | 0.5324 mL | 1.3310 mL | |
| 50 mM | 0.0426 mL | 0.2130 mL | 0.4259 mL | 1.0648 mL | |
| 60 mM | 0.0355 mL | 0.1775 mL | 0.3549 mL | 0.8873 mL | |
| 80 mM | 0.0266 mL | 0.1331 mL | 0.2662 mL | 0.6655 mL | |
| 100 mM | 0.0213 mL | 0.1065 mL | 0.2130 mL | 0.5324 mL |
SETDB1-TTD-IN-1 Related Classifications
HY-141539 Related Classifications
Powered by Bioz